

KUCUK Can, Assoc. Prof., Izmir, Turkey
Dokuz Eylül University, Izmir Biomedicine and Genome Center (IBG)

Dr. Küçük graduated from the Department of Molecular Biology and Genetics at Middle East Technical University (METU) in 2005. He earned his Ph.D degree in Cancer Biology and Oncology from Eppley Institute for Research in Cancer and Allied Diseases at University of Nebraska Medical Center (UNMC) in 2012. He worked as a post-doc in the Department of Pathology at UNMC and then at City of Hope Medical Center. Dr. Can Küçük currently works at İzmir Biomedicine and Genome Center (IBG) at Dokuz Eylül University in Turkey as an associate professor and independent PI with his own research group.

He has authored research articles in high profile journals on molecular pathobiology or diagnostics of NK and/or T cell malignancies. Importantly, one of his first author research articles published in Nature Communications (PMID: 25586472) was cited as the main reference by the World Health Organization (WHO) for renaming and classification of enteropathy-associated T cell lymphoma. Similarly, another paper he authored in Blood (PMID: 24009234) described a novel provisional entity (i.e. "Indolent T-cell lymphoproliferative disease of the gastrointestinal tract"), which was cited as the only reference by WHO. These changes were described in the Blood article (PMID: 26980727), which presented the 2016 revisions of WHO classifications of lymphoid neoplasms.

Dr. Küçük earned the Global Research Award from the American Society of Hematology (ASH), which is the largest professional society in the field of hematology. This is the first award from ASH in its history to a scientist working in Turkey.

His group investigates the etiology of lymphoid malignancies with a perspective of personalized medicine. Dr. Küçük applies genomic, transcriptomic, and epigenomic methodologies on patient samples to improve non-invasive diagnosis and prognosis of lymphoma and multiple myeloma cases through discovery of molecular biomarkers. Furthermore, his group focuses on identification and characterization of novel therapeutic targets.